Breakthrough Inhaled Live Biotherapeutic
Changes in microbial signatures of the lungs and airways are associated with worsening chronic respiratory disease and persistent inflammation.
Alveolus Bio has used over a decade of pulmonary microbiome research and clinical data to inform development of novel inhaled live biotherapeutics that address airway dysbiosis and neutrophilic inflammation.
We have developed AB1000, the first inhaled live biotherapeutic – containing live, viable bacteria – to address chronic and infectious lung disease.
Alveolus Bio’s pre-clinical programs include Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia (BPD), Pulmonary fibrosis, Lung Injury Secondary to Viral Illness, and Neutrophilic (severe) Asthma.